|
|
|
|
|
|
Portfolio Optimization: Health Advances was brought in by the new CEO of an early stage pharmaceutical company to help optimize the company's R&D portfolio.
The company was focused on treatments for genetic diseases. Health Advances screened over 100 genetic diseases on the basis of technical and commercial criteria to prioritize
the company's portfolio and create a clinical development plan to generate maximum value. The project also included an analysis of the company's operational capabilities that
identified the human and capital resources needed to execute the portfolio strategy.
Evaluation and Prioritization of Market Opportunities: Health Advances assessed the market opportunities for a device/drug combination in the area of atherosclerosis.
Health Advances screened over 4,500 drugs in development for potential applications in the identified areas of unmet need for atherosclerosis. This information was incorporated into
a 20-year strategy plan for a large, public healthcare company, based on the above opportunities down to a drug level.
Screening and Prioritization of Target Indications to Drive R&D Strategy: A foreign client had historically pursued the antimicrobial coating applications of its novel
silver technology. Recently, however, the company gained confidence, through anecdotal evidence and in vitro studies, that the same technology could be employed as a pharmaceutical.
In order to focus the necessary research and development, Health Advances was hired to help screen potential pharmaceutical applications for the technology. Health Advances evaluated
a wide range of indications where the client believed it could add the most value, from respiratory to orthopedic to cardiac and more clinical areas. Subsequent phases of the work
delved more deeply into the areas highlighted as promising in this initial screen and further prioritized specific indications, forming the basis for the company's R&D strategy.
Identification, Evaluation and Prioritization of Target Drugs for a Drug Delivery Company: Health Advances evaluated and prioritized over 200 injectible generic
drugs for a mid-tier public drug delivery company with a desire to begin developing drugs for its proprietary portfolio rather than solely with branded partners. The list of
candidates was evaluated against several criteria including the value-based premium that a sustained release version of each drug could warrant, the technical applicability of
technology to each drug versus competitive sustained release technologies, and the future market dynamics in light of current and future branded drug classes
for the same indication(s).
Portfolio and Franchise Strategy: Health Advances identified, screened and developed innovative initiatives to support a large biotech company's major disease
franchise strategy. Activities included extensive internal company interviews, on-site clinic observations, in-person patient and physician interviews, in-depth KOL phone interviews,
and an online specialist survey. Financial analysis focused on calculating return-on-investment for each potential initiative.
In-line Product Franchise Strategy: Health Advances orchestrated a comprehensive strategy development process for the US division of a major pharmaceutical company.
Involving the entire management team, the process involved looking at the strengths and weaknesses of the in-line product portfolio, the functional skills and capabilities, and the
potential opportunities in the context of the competitive and market environment leading to the formulation of the five-year strategic vision for the business.
|
|
 |
|
|
|
|
